遺伝性血液疾患の治療薬開発パイプライン分析2018

GBI Researchが発行した調査報告書(GBIHC048IDB)
◆英語タイトル:Hereditary Hematological Disorders Drug Development Pipeline Review, 2018
◆商品コード:GBIHC048IDB
◆発行会社(リサーチ会社):GBI Research
◆発行日:2018年10月
◆ページ数:143
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,995 ⇒換算¥539,325見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,990 ⇒換算¥1,078,650見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD11,985 ⇒換算¥1,617,975見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GBI Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Hereditary Hematological Disorders Drug Development Pipeline Review, 2018
Summary

This report provides an overview of the pipeline landscape for hereditary hematological disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for thalassemia, hemophilia B and sickle cell anemia, and features dormant and discontinued products.

Thalassemia refers to a group of inherited blood disorders that affect the body’s ability to produce hemoglobin and red blood cells. Symptoms include paleness, frequent infections and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant. There are 40 products in development for this indication.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, nosebleeds and prolonged bleeding from injuries and surgery. Treatment includes replacing the defective clotting factor. There are 42 products in development for this indication.

Sickle cell anemia is a genetic blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. There are 68 products in development for this indication.

Molecular targets acted on by products in development for hereditary hematological disorders include coagulation factors, histone deacetylases and protein kinases. Companies operating in this pipeline space include Sangamo Therapeutics, Gamida Cell and Bluebird Bio.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Hereditary Hematological Disorders Report Coverage 8
2.2 Thalassemia – Overview 8
2.3 Hemophilia B – Overview 8
2.4 Sickle Cell Disease – Overview 8
3 Therapeutics Development 9
3.1 Thalassemia 9
3.2 Hemophilia B – Therapeutics Development 14
3.3 Sickle Cell Disease – Therapeutics Development 20
4 Therapeutics Assessment 28
4.1 Thalassemia – Therapeutics Assessment 28
4.2 Hemophilia B – Therapeutics Assessment 36
4.3 Sickle Cell Disease – Therapeutics Assessment 42
5 Companies Involved in Therapeutics Development 49
5.1 Thalassemia – Companies Involved in Therapeutics Development 49
5.2 Hemophilia B – Companies Involved in Therapeutics Development 59
5.3 Sickle Cell Disease – Companies Involved in Therapeutics Development 72
6 Dormant Projects 93
6.1 Thalassemia – Dormant Projects 93
6.2 Hemophilia B – Dormant Projects 94
6.3 Sickle Cell Disease – Dormant Projects 95
7 Discontinued Products 98
7.1 Thalassemia – Discontinued Products 98
7.2 Hemophilia B – Discontinued Products 98
8 Product Development Milestones 99
8.1 Thalassemia – Product Development Milestones 99
8.2 Hemophilia B – Product Development Milestones 114
8.3 Sickle Cell Disease – Product Development Milestones 127
9 Appendix 142
9.1 Methodology 142
9.2 Coverage 142
9.3 Secondary Research 142
9.4 Primary Research 142
9.5 Expert Panel Validation 142
9.6 Contact Us 143
9.7 Disclaimer 143

1.1 List of Tables
Table 1: Number of Products under Development for Thalassemia 9
Table 2: Number of Products under Development by Companies, Thalassemia 10
Table 3: Number of Products under Development by Universities/Institutes, Thalassemia 12
Table 4: Products under Development by Companies, Thalassemia 12
Table 5: Products under Development by Universities/Institutes, Thalassemia 14
Table 6: Number of Products under Development for Hemophilia B 15
Table 7: Number of Products under Development by Companies, Hemophilia B 16
Table 8: Number of Products under Development by Universities/Institutes, Hemophilia B 17
Table 9: Products under Development by Companies, Hemophilia B 18
Table 10: Products under Development by Universities/Institutes, Hemophilia B 20
Table 11: Number of Products under Development for Sickle Cell Disease 21
Table 12: Number of Products under Development by Companies, Sickle Cell Disease 22
Table 13: Number of Products under Development by Universities/Institutes, Sickle Cell Disease 24
Table 14: Products under Development by Companies, Sickle Cell Disease 24
Table 15: Products under Development by Universities/Institutes, Sickle Cell Disease 27
Table 16: Number of Products by Stage and Target, Thalassemia 30
Table 17: Number of Products by Stage and Mechanism of Action, Thalassemia 32
Table 18: Number of Products by Stage and Route of Administration, Thalassemia 34
Table 19: Number of Products by Stage and Molecule Type, Thalassemia 35
Table 20: Number of Products by Stage and Target, Hemophilia B 37
Table 21: Number of Products by Stage and Mechanism of Action, Hemophilia B 38
Table 22: Number of Products by Stage and Route of Administration, Hemophilia B 40
Table 23: Number of Products by Stage and Molecule Type, Hemophilia B 41
Table 24: Number of Products by Stage and Target, H2 2018, Sickle Cell Disease 43
Table 25: Number of Products by Stage and Mechanism of Action, Sickle Cell Disease 45
Table 26: Number of Products by Stage and Route of Administration, Sickle Cell Disease 47
Table 27: Number of Products by Stage and Molecule Type, Sickle Cell Disease 48
Table 28: Thalassemia - Pipeline by Acceleron Pharma Inc 49
Table 29: Thalassemia - Pipeline by Agios Pharmaceuticals Inc 50
Table 30: Thalassemia - Pipeline by bluebird bio Inc 50
Table 31: Thalassemia - Pipeline by Cadila Healthcare Ltd, 51
Table 32: Thalassemia - Pipeline by Calimmune Inc 51
Table 33: Thalassemia - Pipeline by CRISPR Therapeutics 52
Table 34: Thalassemia - Pipeline by Editas Medicine Inc 53
Table 35: Thalassemia - Pipeline by Errant Gene Therapeutics LLC 53
Table 36: Thalassemia - Pipeline by Gamida Cell Ltd 53
Table 37: Thalassemia - Pipeline by Gilead Sciences Inc 54
Table 38: Thalassemia - Pipeline by Incyte Corp 55
Table 39: Thalassemia - Pipeline by Ionis Pharmaceuticals Inc 55
Table 40: Thalassemia - Pipeline by Kiadis Pharma NV 56
Table 41: Thalassemia - Pipeline by La Jolla Pharmaceutical Company 56
Table 42: Thalassemia - Pipeline by Merck & Co Inc 57
Table 43: Thalassemia - Pipeline by Poseida Therapeutics Inc 57
Table 44: Thalassemia - Pipeline by Protagonist Therapeutics Inc 58
Table 45: Thalassemia - Pipeline by Sangamo Therapeutics Inc 58
Table 46: Thalassemia - Pipeline by Silence Therapeutics Plc 59
Table 47: Thalassemia - Pipeline by Vifor Pharma AG 59
Table 48: Hemophilia B - Pipeline by Amarna Therapeutics BV 60
Table 49: Hemophilia B - Pipeline by Bayer AG 60
Table 50: Hemophilia B - Pipeline by Bioverativ Inc 61
Table 51: Hemophilia B - Pipeline by Catalyst Biosciences Inc 62
Table 52: Hemophilia B - Pipeline by China Biologic Products Inc 62
Table 53: Hemophilia B - Pipeline by CSL Ltd 63

1.2 List of Figures
Figure 1: Number of Products under Development for Thalassemia 9
Figure 2: Number of Products under Development by Companies, Thalassemia 10
Figure 3: Number of Products under Development by Universities/Institutes, Thalassemia 11
Figure 4: Number of Products under Development for Hemophilia B 14
Figure 5: Number of Products under Development by Companies, Hemophilia B 15
Figure 6: Number of Products under Development by Universities/Institutes, Hemophilia B 17
Figure 7: Number of Products under Development for Sickle Cell Disease 20
Figure 8: Number of Products under Development by Companies, Sickle Cell Disease 21
Figure 9: Number of Products under Development by Universities/Institutes, Sickle Cell Disease 23
Figure 10: Number of Products by Top 10 Targets, Thalassemia 28
Figure 11: Number of Products by Stage and Top 10 Targets, Thalassemia 29
Figure 12: Number of Products by Top 10 Mechanism of Actions, Thalassemia 31
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Thalassemia 31
Figure 14: Number of Products by Routes of Administration, Thalassemia 33
Figure 15: Number of Products by Stage and Routes of Administration, Thalassemia 33
Figure 16: Number of Products by Molecule Types, Thalassemia 34
Figure 17: Number of Products by Stage and Molecule Types, Thalassemia 35
Figure 18: Number of Products by Targets, Hemophilia B 36
Figure 19: Number of Products by Stage and Targets, Hemophilia B 36
Figure 20: Number of Products by Mechanism of Actions, Hemophilia B 37
Figure 21: Number of Products by Stage and Mechanism of Actions, Hemophilia B 38
Figure 22: Number of Products by Routes of Administration, Hemophilia B 39
Figure 23: Number of Products by Stage and Routes of Administration, Hemophilia B 39
Figure 24: Number of Products by Molecule Types, Hemophilia B 40
Figure 25: Number of Products by Stage and Molecule Types, Hemophilia B 41
Figure 26: Number of Products by Top 10 Targets, Sickle Cell Disease 42
Figure 27: Number of Products by Stage and Top 10 Targets, Sickle Cell Disease 42
Figure 28: Number of Products by Top 10 Mechanism of Actions, Sickle Cell Disease 44
Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Sickle Cell Disease 44
Figure 30: Number of Products by Routes of Administration, Sickle Cell Disease 46
Figure 31: Number of Products by Stage and Routes of Administration, Sickle Cell Disease 46
Figure 32: Number of Products by Top 10 Molecule Types, Sickle Cell Disease 47
Figure 33: Number of Products by Stage and Top 10 Molecule Types, Sickle Cell Disease 48

【掲載企業】

Neuritis
AC Immune SA
Aerie Pharmaceuticals Inc
Alkeus Pharmaceuticals Inc
Allergan Plc
Altacor Ltd
Amarantus Bioscience Holdings Inc
Annexon Inc
Astellas Pharma Inc
Bactevo Ltd
Bial - Portela & Ca SA
BioAxone BioSciences Inc
Bionure Farma SL
Biovista Inc
Can-Fite BioPharma Ltd
Cellix Bio Pvt Ltd
Certa Therapeutics Pty Ltd
Chong Kun Dang Pharmaceutical Corp
coma
Commence Bio Inc
D. Western Therapeutics Institute Inc
Disarm Therapeutics Inc
Dompe Farmaceutici SpA
Elsalys Biotech SA
EyePoint Pharmaceuticals Inc
Eyevensys SAS
Fortify Therapeutics Inc
Fortress Biotech Inc
Gene Signal International SA
GenSight Biologics SA
Glaukos Corp
Graybug Vision Inc
Han Wha Pharma Co Ltd
Handok Inc
HitGen LTD
ID Pharma Co Ltd
InMed Pharmaceuticals Inc
Inspyr Therapeutics Inc
Ironwood Pharmaceuticals Inc
Isarna Therapeutics GmbH
Ixchel Pharma LLC
Khondrion BV
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Laboratorios SALVAT SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
Lipocure Ltd
Meta-IQ ApS
MimeTech Srl
Mitobridge Inc
Mitochon Pharmaceuticals Inc
Mitotech SA
Nemus Bioscience Inc
Neurim Pharmaceuticals Ltd
NicOx SA
NoNO Inc
Novaliq GmbH
Novartis AG
Ocular Therapeutix Inc
Oculis ehf
Ohr Pharmaceutical Inc
Oncolys BioPharma Inc
Pivot Pharmaceuticals Inc
Profarma
Q BioMed Inc
Regenera Pharma Ltd
ReNetX Bio
Santen Pharmaceutical Co Ltd
Santhera Pharmaceuticals Holding AG
Senju Pharmaceutical Co Ltd
Shire Plc
Spark Therapeutics Inc
Stealth BioTherapeutics Inc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
Taejoon Pharm Co Ltd
Teijin Pharma Ltd
TikoMed AB
Unity Biotechnology Inc

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 遺伝性血液疾患の治療薬開発パイプライン分析2018(Hereditary Hematological Disorders Drug Development Pipeline Review, 2018)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆